Headquartered in Boston, Ginkgo Bioworks uses the most advanced technology on the planet—biology—to grow better products. Our cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals.

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in ...

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals.

About Ginkgo Corporate Profile. Headquartered in Boston, Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers. Our cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals.

Find the latest Ginkgo Bioworks Holdings, Inc. (DNA) stock quote, history, news and other vital information to help you with your stock trading and investing.

At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications.

Aug 24, 2021 · The Boston genetic engineering company Ginkgo Bioworks and its CEO, Jason Kelly, have been spectacularly successful selling a story: that synthetic biology will transform the manufacture of ...

The Ginkgo tree is arguably the most sustainable plant in the history of the world, with a magnificent design that has survived over 200 million years of existence. The Ginkgo defines our ideal as a company: strong, deep-rooted, adaptable and tenacious.

Jan 24, 2023 · Ginkgo Bioworks is getting ready for another year of disrupting the entire biotech industry model with its versatile menu of biology engineering services. As a full-stack synthetic biology...

Mar 5, 2025 · Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.